A Phase 1 Study of IPI-145 in Patients with Advanced Hematologic Malignancies


For Dose Escalation/MTD Confirmation Only: Diagnosis of any advanced hematologic malignancy other than acute leukemia, CML in blast crisis and high risk or intermediate type 2 myelodysplastic syndrome. | For Expansion Cohort 1 Only: Diagnosis of indolent non- Hodgkin lymphoma (iNHL), mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL). | For Expansion Cohort 2 Only: Diagnosis of mature cutaneous or non-cutaneous T cell lymphomas (excluding lymphoblastic lymphoma). | For Expansion Cohort 3 Only: Diagnosis of diffuse large B-cell lymphoma (DLBCL) or transformed follicular NHL. | For Expansion Cohort 4 Only: Diagnosis of myeloproliferative neoplasms (myelofibrosis and all phases of CML), AML, MDS (including intermediate and high risk). | For Expansion Cohort 5 Only: Diagnosis of acute lymphocytic leukemia/lymphoblastic lymphoma (T-cell or B-cell).

What is the purpose of this trial?

The purpose of this study is to determine the safety, maximum tolerated dose and pharmacokinetics of IPI-145 in patients with advanced hematologic malignancies.

Participation Guidelines

18 Years and older

Click here for detailed information about who can participate in this trial.

Infinity Pharmaceuticals, Inc.
November 2012
Last Updated:
Study HIC#: